Small, open label study of 43 RA pts Rx w/ csDMARDs randomized to denosumab or PBO x 24 weeks. Erosions of MCP 2,3 assessed by HR-pQCT shows no significant differences in erosions or safety signals at 6 mos between groups. https://t.co/AuysVPFD4S https://t.co/yQ4R41hSMi